Antibody development includes:
In vitro display technologies offer unique advantages over hybridoma technology, particularly for challenging targets like integral membrane proteins.
iMAb uses proprietary computer-designed synthetic repertoires of human mAbs optimized for diversity, expression, and affinity for in vitro screening.
iMAb is a biotech company with an integrated approach to develop human antibodies.
The company was spun out from Inserm and uses proprietary know-how and a highly diverse library containing billions of candidate antibodies.
(*) > 30 (academic) programs including: GPCR agonists, enzyme inhibitors, anti-splicing-variants, anti-post-translational modifications, anti-receptor tyrosine kinases, anti-ligand, ... (many of them cross-reactive human/mouse)
iMAb, Institut de Recherche en Cancérologie de Montpellier, Campus Val d'Aurelle, 34298 Montpellier cedex 5, France